Using an AI platform developed by CytoReason, London-headquartered Poolbeg Pharma has been analysing flu human challenge trials data since March 2022.
Read more: Poolbeg Pharma identifies new flu drug targets using AI
Using an AI platform developed by CytoReason, London-headquartered Poolbeg Pharma has been analysing flu human challenge trials data since March 2022.
Read more: Poolbeg Pharma identifies new flu drug targets using AI
